These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 30166456)

  • 1. Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy.
    Dantonio PM; Klein MO; Freire MRVB; Araujo CN; Chiacetti AC; Correa RG
    Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30166456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic regulation in human melanoma: past and future.
    Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME
    Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MED27 promotes melanoma growth by targeting AKT/MAPK and NF-κB/iNOS signaling pathways.
    Tang R; Xu X; Yang W; Yu W; Hou S; Xuan Y; Tang Z; Zhao S; Chen Y; Xiao X; Huang W; Guo W; Li M; Deng W
    Cancer Lett; 2016 Apr; 373(1):77-87. PubMed ID: 26797421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting drivers of melanoma with synthetic small molecules and phytochemicals.
    Strickland LR; Pal HC; Elmets CA; Afaq F
    Cancer Lett; 2015 Apr; 359(1):20-35. PubMed ID: 25597784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Lim SY; Menzies AM; Rizos H
    Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling.
    Paluncic J; Kovacevic Z; Jansson PJ; Kalinowski D; Merlot AM; Huang ML; Lok HC; Sahni S; Lane DJ; Richardson DR
    Biochim Biophys Acta; 2016 Apr; 1863(4):770-84. PubMed ID: 26844774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT3 targeting by polyphenols: Novel therapeutic strategy for melanoma.
    Momtaz S; Niaz K; Maqbool F; Abdollahi M; Rastrelli L; Nabavi SM
    Biofactors; 2017 May; 43(3):347-370. PubMed ID: 27896891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of MAPKs, Myc/Max, NFκB, and hypoxia pathways by Phyllanthus prevents proliferation, metastasis and angiogenesis in human melanoma (MeWo) cancer cell line.
    Tang YQ; Jaganath IB; Manikam R; Sekaran SD
    Int J Med Sci; 2014; 11(6):564-77. PubMed ID: 24782645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional and therapeutic significance of Akt deregulation in malignant melanoma.
    Robertson GP
    Cancer Metastasis Rev; 2005 Jun; 24(2):273-85. PubMed ID: 15986137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenetics of melanoma: basis for molecular diagnostics and therapy.
    Held L; Eigentler TK; Meier F; Held M; Röcken M; Garbe C; Bauer J
    J Dtsch Dermatol Ges; 2011 Jul; 9(7):510-6. PubMed ID: 21244632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives.
    Fang Z; Meng Q; Xu J; Wang W; Zhang B; Liu J; Liang C; Hua J; Zhao Y; Yu X; Shi S
    Cancer Commun (Lond); 2023 Jan; 43(1):3-41. PubMed ID: 36424360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy.
    Hao J; Xu H; Luo M; Yu W; Chen M; Liao Y; Zhang C; Zhao X; Jiang W; Hou S; Feng X; Zou K; Chen Y; Huang W; Guo W; Kang L; Deng W
    J Invest Dermatol; 2018 Jan; 138(1):159-170. PubMed ID: 28899685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation and tumor progression: signaling pathways and targeted intervention.
    Zhao H; Wu L; Yan G; Chen Y; Zhou M; Wu Y; Li Y
    Signal Transduct Target Ther; 2021 Jul; 6(1):263. PubMed ID: 34248142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Understanding current therapies in metastatic melanoma].
    Rodríguez R; Parra A; González S; Molgó M; Droppelmann N; Acevedo F; Peña J; Uribe P
    Rev Med Chil; 2016 Nov; 144(11):1448-1458. PubMed ID: 28394962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX; Qi XY
    IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting multiple key signaling pathways in melanoma using leelamine.
    Gowda R; Madhunapantula SV; Kuzu OF; Sharma A; Robertson GP
    Mol Cancer Ther; 2014 Jul; 13(7):1679-89. PubMed ID: 24688050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies for cutaneous melanoma.
    Kee D; McArthur G
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nuclear beta-catenin localization is not sufficient for canonical Wnt signaling activation in human meianoma cell lines].
    Kulikova KV; Posviatenko AV; Gnuchev NV; Georgiev GP; Kibardin AV; Larin SS
    Mol Biol (Mosk); 2011; 45(5):884-91. PubMed ID: 22393786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.